The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis

@article{Patel2000TheUO,
  title={The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis},
  author={Anand H Patel and Denise M. Harnois and George G. Klee and Nicholas F. LaRusso and Gregory J. Gores},
  journal={American Journal of Gastroenterology},
  year={2000},
  volume={95},
  pages={204-207}
}
OBJECTIVES:The diagnosis of cholangiocarcinoma is often difficult, making management approaches problematic. A reliable serum tumor marker for cholangiocarcinoma would be a useful additional diagnostic test. Previous studies have demonstrated that elevated serum concentrations of CA 19-9, a tumor-associated antigen, have good sensitivity and specificity for cholangiocarcinoma in patients with primary sclerosing cholangitis. However, the value of this tumor marker for cholangiocarcinoma… 

Figures and Tables from this paper

Is a Raised CA 19-9 Level Diagnostic for a Cholangiocarcinoma in Patients with No History of Sclerosing Cholangitis ?

It is demonstrated that CA 19-9 is a useful adjunct in the diagnosis of cholangiocarcinomas without primary sclerosing cholangsitis, however, it does not provide a reliable guide for the pathological staging of these tumours.

The Value of Serum CA 19-9 in Predicting Cholangiocarcinomas in Patients with Primary Sclerosing Cholangitis

The positive predictive value of an elevated CA 19-9 was 56.6%; only advanced cases were detected by this method.

Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study.

Preliminary results suggest that the measurement of all four biomarkers together can help in the early detection of cholangiocarcinoma.

Inflammation But Not Biliary Obstruction Is Associated With Carbohydrate Antigen 19-9 Levels in Patients With Primary Sclerosing Cholangitis.

  • A. WannhoffC. Rupp D. Gotthardt
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2015

Serum Markers of Intrahepatic Cholangiocarcinoma

New markers such as Soluble fragment of cytokeratin 19 (CYFRA 21-1) Mucins, Tumour Markers2- pyruvate-Kinase (TuM2- PK) and metalloproteinase-7 (MMP-7) have been recently shown to help in the diagnosis of CCA, with in some cases a prognostic value.

Diagnostic Accuracy of Serum CA19-9 in Patients with Cholangiocarcinoma: A Systematic Review and Meta-Analysis

Serum CA19-9 is a useful non-invasive biomarker for CCA detection and may become a clinically useful tool to identify high-risk patients.

Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy

Serum MMP-7 appears to be a valuable diagnostic marker in the discrimination of cholangiocarcinoma from benign biliary tract diseases patients in comparison to carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9).

Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma.

Serum values of MMP7 and CA19-9 appear to be useful biomarkers for differentiating cholangiocarcinoma from benign biliary tract obstructive diseases.

The Detection of Cholangiocarcinoma in Primary Sclerosing Cholangitis Patients: Single Center Experience

Brush cytology has moderate sensitivity in differentiating strictures in PSC patients and CA 19-9 has high sensitivity but bilirubin level can affect the CA19-9, therefore, advanced techniques and parameters are needed for detecting CCA in P SC patients.

Dilemma of elevated CA 19-9 in biliary pathology.

...

References

SHOWING 1-10 OF 17 REFERENCES

Prospective evaluation of the diagnostic efficacy of CA 19-9 assay as a marker for gastrointestinal cancers.

It is concluded that CA 19-9 is a marker of epithelial cancers, does not vary with the smoking status, and is superior to CEA in detecting gastrointestinal malignancies, especially those arising from the pancreatic gland.

Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.

The results indicate that the CA 19-9 assay is not completely specific for cancer but serves as a valuable adjunct, especially in the diagnosis of pancreatic carcinoma, and alpha-fetoprotein was a better marker for hepatomas than CA19-9.

Initial clinical evaluation of an immunoradiometric assay for CA 19‐9 using the nci serum bank

The improved CA 19‐9 immunoradiometric assay may have clinical utility as a diagnostic adjunct for adenocarcinoma of the upper GI tract and that the assay also may have some value in monitoring patients with advancing colorectal carcinoma, particularly in combination with CEA determinations.

Cytodiagnosis in the management of extrahepatic biliary stricture.

Cytodiagnosis of extrahepatic biliary strictures is a safe procedure which is not technically demanding, and as it has a high sensitivity and predictive value for positive cytology, cytological confirmation of malignancy should be sought in all clinically and radiologically suspicious cases.

Carbohydrate antigenic determinant (CA 19-9) and other tumor markers in gastrointestinal malignancies.

A significant difference in CA 19-9 was found between patients with pancreatic cancer and gastric cancer, other gastrointestinal (GI) malignancies, other non-GI malignancy, benign digestive diseases or normal populations.

Value of exfoliative cytology for investigating bile duct strictures.

Exfoliative biliary cytology was evaluated in 62 patients with biliary tract strictures presenting to the Hepatobiliary Unit and the results are highly specific and should be a routine part of the investigation of biliary strictures.

CA 19-9 in pancreatic cancer.